Targets › IFNGR1
3 programs from 3 companies in 3 trials: 3 Phase 2; Infectious disease, Oncology; next expected readout Nov 2026.
Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. (UniProt, P15260)
Open in Phaseline: the race on IFNGR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Manchester University NHS Foundation Trust | Interferon Gamma-1B Interferon gamma receptor agonist | IFNGR2, IFNGR1 | Phase 2 | Chronic Pulmonary Aspergillosis | Nov 2026 |
| University Hospital, Basel, Switzerland | Interferon Gamma-1B Interferon gamma receptor agonist | IFNGR2, IFNGR1 | Phase 2 | Adenovirus Infection | Dec 2026 |
| Sawa Ito, MD | Interferon gamma-1b Interferon gamma receptor agonist | IFNGR2, IFNGR1 | Phase 2 | Acute Myeloid Leukemia | Oct 2029 |
Acute Myeloid Leukemia (1) Chronic Pulmonary Aspergillosis (1) Adenovirus Infection (1)
protein or peptide (1), other (1)
Sawa Ito, MD (1) Manchester University NHS Foundation Trust (1) University Hospital, Basel, Switzerland (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.